Dermata Therapeutics(DRMA) - 2024 Q3 - Quarterly Results

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 – SAN DIEGO, CA, November 13, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRM ...